Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
Mai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San Diego Healthcare System, San Diego, 4Department of...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-11-01
|
| Series: | Infection and Drug Resistance |
| Online Access: | http://www.dovepress.com/ceftolozanetazobactam-a-novel-antipseudomonal-cephalosporin-and-beta-l-a15132 |
| _version_ | 1818199495974846464 |
|---|---|
| author | Hong MC Hsu DI Bounthavong M |
| author_facet | Hong MC Hsu DI Bounthavong M |
| author_sort | Hong MC |
| collection | DOAJ |
| description | Mai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San Diego Healthcare System, San Diego, 4Department of Pharmacy Practice, University of California, San Diego, CA, USAAbstract: The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians. Ceftolozane/tazobactam is a novel antibacterial and β-lactamase-inhibitor combination that has shown appreciable activity against wild-type Enterobacteriaceae and potent activity against P. aeruginosa. Moreover, ceftolozane/tazobactam has not demonstrated cross-resistance to other antimicrobial classes, particularly those affected by extended-spectrum β-lactamases, AmpC β-lactamase, a loss in porin channels, or the overexpression of efflux pumps in P. aeruginosa. Ceftolozane/tazobactam has completed two Phase II clinical trials in complicated intra-abdominal and complicated urinary tract infections. A Phase III, multicenter, prospective, randomized, open-label study has been initiated to evaluate the safety and efficacy of ceftolozane/tazobactam versus piperacillin/tazobactam for the treatment of ventilator-associated pneumonia. A Medline search of articles from inception to May 2013 and references for selected citations was conducted. Data from abstracts presented at conferences were also appraised. This article reviews the antimicrobial, pharmacokinetic, and pharmacodynamic profile of ceftolozane/tazobactam, and discusses its potential role in therapy.Keywords: CXA-201, CXA-101, FR264205, Pseudomonas aeruginosa |
| first_indexed | 2024-12-12T02:22:41Z |
| format | Article |
| id | doaj.art-7ea194d7b0834815bb65137012b4982b |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-12-12T02:22:41Z |
| publishDate | 2013-11-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-7ea194d7b0834815bb65137012b4982b2022-12-22T00:41:38ZengDove Medical PressInfection and Drug Resistance1178-69732013-11-012013default215223Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combinationHong MCHsu DIBounthavong MMai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San Diego Healthcare System, San Diego, 4Department of Pharmacy Practice, University of California, San Diego, CA, USAAbstract: The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians. Ceftolozane/tazobactam is a novel antibacterial and β-lactamase-inhibitor combination that has shown appreciable activity against wild-type Enterobacteriaceae and potent activity against P. aeruginosa. Moreover, ceftolozane/tazobactam has not demonstrated cross-resistance to other antimicrobial classes, particularly those affected by extended-spectrum β-lactamases, AmpC β-lactamase, a loss in porin channels, or the overexpression of efflux pumps in P. aeruginosa. Ceftolozane/tazobactam has completed two Phase II clinical trials in complicated intra-abdominal and complicated urinary tract infections. A Phase III, multicenter, prospective, randomized, open-label study has been initiated to evaluate the safety and efficacy of ceftolozane/tazobactam versus piperacillin/tazobactam for the treatment of ventilator-associated pneumonia. A Medline search of articles from inception to May 2013 and references for selected citations was conducted. Data from abstracts presented at conferences were also appraised. This article reviews the antimicrobial, pharmacokinetic, and pharmacodynamic profile of ceftolozane/tazobactam, and discusses its potential role in therapy.Keywords: CXA-201, CXA-101, FR264205, Pseudomonas aeruginosahttp://www.dovepress.com/ceftolozanetazobactam-a-novel-antipseudomonal-cephalosporin-and-beta-l-a15132 |
| spellingShingle | Hong MC Hsu DI Bounthavong M Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination Infection and Drug Resistance |
| title | Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination |
| title_full | Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination |
| title_fullStr | Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination |
| title_full_unstemmed | Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination |
| title_short | Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination |
| title_sort | ceftolozane tazobactam a novel antipseudomonal cephalosporin and beta lactamase inhibitor combination |
| url | http://www.dovepress.com/ceftolozanetazobactam-a-novel-antipseudomonal-cephalosporin-and-beta-l-a15132 |
| work_keys_str_mv | AT hongmc ceftolozanetazobactamanovelantipseudomonalcephalosporinandbetalactamaseinhibitorcombination AT hsudi ceftolozanetazobactamanovelantipseudomonalcephalosporinandbetalactamaseinhibitorcombination AT bounthavongm ceftolozanetazobactamanovelantipseudomonalcephalosporinandbetalactamaseinhibitorcombination |